Prophylaxe thromboembolischer Erkrankungen mit Rivaroxaban

Literatur

• 1 Eriksson B I, Borris L C, Friedman R J. et al . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.  N Engl J Med. 2008;  358 2765-2775
  Google Scholar
• 2 Kakkar A K, Brenner B, Dahl O E. et al . Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.  Lancet. 2008;  372 31-39
  Google Scholar
• 3 Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59 – 7939) – an oral, direct Factor Xa inhibitor – has no clinically relevant interaction with naproxen.  Br J Clin Pharmacol. 2007;  63 469-476
  Google Scholar
• 4 Kubitza D, Becka M, Wensing G. et al . Safety, pharmacodynamics, and pharmacokinetics of BAY 59 – 7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects.  Eur J Clin Pharmacol. 2005;  61 873-880
  Google Scholar
• 5 Lassen M R, Ageno W, Borris L C. et al . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.  N Engl J Med. 2008;  358 2776-2786
  Google Scholar
• 6 Mueck W, Becka M, Kubitza D. et al . Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor xa inhibitor – in healthy subjects.  Int J Clin Pharmacol Ther. 2007;  45 335-344
  Google Scholar
• 7 Perzborn E, Strassburger J, Wilmen A. et al . In vitro and in vivo studies of the novel antithrombotic agent BAY 59 – 7939 – an oral, direct Factor Xa inhibitor.  J Thromb Haemost. 2005;  3 514-521
  Google Scholar
• 8 Turpie A G, Lassen M R, Davidson B L. et al . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.  Lancet. 2009;  373 673-1680
  Google Scholar

Dr. Natig Gassanov

Herzzentrum Köln
Klinik III für Innere Medizin

Kerpener Str. 62

50924 Köln

Phone: 0221/47832544

Fax: 0221/47832712

Email: Natig.Gassanov@uk-koeln.de